Valbenazine Ditosylate is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor used clinically in the treatment of tardive dyskinesia. By reversibly inhibiting the VMAT2 protein, this pharmaceutical… Read more
Valbenazine Ditosylate is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor used clinically in the treatment of tardive dyskinesia. By reversibly inhibiting the VMAT2 protein, this pharmaceutical agent reduces the presynaptic packaging and subsequent release of dopamine, thereby mitigating the involuntary movements associated with this hyperkinetic disorder. To ensure the safety and efficacy of the drug, analytical laboratories rely on a comprehensive range of related compounds, including impurities, metabolites, and stable isotope-labelled standards. These reference materials are critical for accurate impurity profiling and method validation, allowing researchers to monitor degradation products and quantify active substances during quality control processes. By utilizing these high-quality standards in bioanalytical studies and stability-indicating methods, such as HPLC and LC-MS, laboratories can maintain rigorous standards of chemical purity and confirm the integrity of Valbenazine Ditosylate throughout its pharmaceutical lifecycle.